Atossa Therapeutics (ATOS) to Release Earnings on Tuesday

Atossa Therapeutics (NASDAQ:ATOS) will likely be posting its quarterly earnings results on Tuesday, March 25th. Analysts expect Atossa Therapeutics to post earnings of ($0.06) per share for the quarter.

Atossa Therapeutics Price Performance

NASDAQ:ATOS opened at $0.72 on Friday. The firm has a market capitalization of $90.01 million, a price-to-earnings ratio of -3.25 and a beta of 1.20. The company’s 50-day moving average is $0.81 and its two-hundred day moving average is $1.13. Atossa Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.31.

Hedge Funds Weigh In On Atossa Therapeutics

An institutional investor recently raised its position in Atossa Therapeutics stock. Bank of America Corp DE lifted its stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 111,475 shares of the company’s stock after acquiring an additional 37,809 shares during the quarter. Bank of America Corp DE owned 0.09% of Atossa Therapeutics worth $105,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 12.74% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Atossa Therapeutics in a report on Wednesday, March 12th. Ascendiant Capital Markets boosted their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.